FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?

Invasive functional measurement of intermediate lesions has become the gold standard to define revascularization. Due to its favorable long-term prognostic value, fractional flow reserve (FFR) is the reference used to compare all others.

FFR e iFR discordantes hasta en un 20% de los casos ¿con cuál decidimos?

Recently, new nonhyperemic indexes, measured in a specific diastolic period, have emerged. Among them, the one with the most accumulated evidence is instantaneous wave-free ratio (iFR), which is just as helpful as FFR when it comes to decision-making, while being more practical and faster.

When FFR and iFR results match, revascularization is already decided. However, in up to 20% of cases there is a discordance in measurements, leaving the operator with a dilemma.

Multiple studies have compared angiography with FFR, and FFR vs. iFR.

Results from FAME, FAME 2, and DEFER showed a clinical benefit of using FFR vs. angiography for revascularization guidance, as well as the safety of deferring these lesions when their measurement was negative.


Read also: TCT 2020 | Crushed Prasugrel Administration prior PCI.


The DEFINE-FLAIR and iFR-SWEDEHEART trials showed noninferiority of iFR vs. FFR for lesion revascularization or deferral.

All of this evidence was compiled in the 2018 European guidelines, which provided a class IA recommendation for both indexes.

Clinical practice pushed iFR because it is faster to measure, cheaper, and presents fewer adenosine adverse events.


Read also: TCT 2020 | Surprising Differences in Stroke between SAPIEN 3 and Evolut R.


However, FFR and iFR equivalence has been challenged because of the frequent incidence of discordant results.

The 3V FFR-FRIENDS study, recently published in JAHA, compared nonhyperemic indexes vs. FFR at 5 years. This follow-up length seems very reasonable to finally answer these questions about FFR and iFR.

The analysis included 1024 vessels in 435 patients who were measured by FFR and nonhyperemic indexes, such as iFR.


Read also: TCT 2020 | Fewer Symptoms and Events when Optimizing with iFR.


The study population was divided into three groups: revascularization with FFR ≤0.80; deferred lesions according to negative concordant FFR and iFR, and deferred lesions with discordant FFR and iFR results.

The rates of combined events (cardiac death, vessel-related infarction, and ischemia-driven revascularization) at 5 years were 14.8%, 7.5%, and 14.4% for revascularized patients, concordant deferred patients, and discordant deferred patients, respectively.

Results show a similar prognosis for concordant positive values (≤0.89 or ≤0.80 for iFR or FFR, respectively).

The group of patients deferred with discordant values showed more events than the concordant deferred group. However, these events were less than the number of events in the revascularization group. Deferring based on any index is a reasonable option. Conversely, choosing revascularization does not worsen patient prognosis.

Original Title: Long-Term Clinical Outcomes of Nonhyperemic Pressure Ratios: Resting Full-Cycle Ratio, Diastolic Pressure Ratio, and Instantaneous Wave-Free Ratio.

Reference: Joo Myung Lee et al. J Am Heart Assoc. 2020;9:e016818. DOI: 10.1161/JAHA.120.016818.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...